Hightide Therapeutics Inc

As of December 31, 2025, Hightide Therapeutics Inc carries a market capitalization of 1.50B, placing it among publicly traded companies globally. Its enterprise value stands at 1.15B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hightide Therapeutics Inc's next confirmed earnings release is scheduled for March 26, 2027.

As of December 31, 2025, Hightide Therapeutics Inc has 508.71M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Hightide Therapeutics Inc maintains a current ratio of 5.41, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Hightide Therapeutics Inc's stock has declined approximately 11.58% over the past 52 weeks. The 50-day moving average sits at 3.31, while the 200-day moving average is 3.10.

As of December 31, 2025, Hightide Therapeutics Inc holds 559.48M in cash and equivalents against 141.19M in total debt, resulting in a net debt position of -136.20M. Total book value stands at 341.67M, with working capital of 482.88M providing operational flexibility.